IP Library Patent Application 17361903
Patent Application
App. No. 17/361,903

METHODS FOR DIAGNOSING LHRH OR hCG/LH RECEPTOR EXPRESSING TUMORS, CANCERS AND NEOPLASIAS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/361,903
Abstract

The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.

Claims (9)

1 . A method of analyzing a prostate, ovarian, breast or endometrial sample, the method comprising:

(a) contacting the prostate, ovarian, breast or endometrial sample from a subject, with a hormone polypeptide or hormone polypeptide analog that binds to LHRH- or hCG/LH receptors under conditions allowing the hormone or hormone analog to bind the LHRH- or hCG/LH receptors;

(b) determining an amount of LHRH- or hCG/LH receptors in the sample by detecting the amount of hormone polypeptide or hormone polypeptide analog that is bound to the LHRH- or hCG/LH receptors in the sample;

(c) contacting cells obtained from the sample with a peptide comprising the cytotoxic sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG (SEQ ID NO: 1); and

(d) after the contacting of (c), determining the IC50 value according to a sensitivity of the cells to SEQ ID NO:1, wherein the IC50 value is 5.5 μM or less and wherein greater LHRH- or hCG/LH receptor expression indicates increased sensitivity of the cells.

2 . The method of claim 1 , comprising identifying a sample according to the determining of (b), wherein greater than 50% of the cells express LHRH- or hCG/LH receptors.

3 . The method of claim 1 , wherein the cytotoxic sequence is biotin-conjugated.

4 . The method of claim 1 , wherein the hormone polypeptide or hormone polypeptide analog comprises one or more D-amino acids.

5 . The method of claim 1 , wherein the hormone polypeptide or hormone polypeptide analog is biotin-conjugated.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: ESPERANCE PHARMACEUTICALS INC.
To: A28 THERAPEUTICS INC.
Reel/Frame 059971/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2021
From: LEUSCHNER, CAROLA; ALILA, HECTOR
To: ESPERANCE PHARMACEUTICALS, INC.
Reel/Frame 056704/0883 →